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Aim To determine the relationship between bilateral allo-
dynia induced by masseter inflammation and P2X3 recep-
tor expression changes in trigeminal ganglia (TRG) and the 
influence of intramasseteric P2X3 antagonist administra-
tion on bilateral masseter allodynia.
Methods To induce bilateral allodynia, rats received a uni-
lateral injection of complete Freund’s adjuvant (CFA) into 
the masseter muscle. Bilateral head withdrawal threshold 
(HWT) was measured 4 days later. Behavioral measure-
ments were followed by bilateral masseter muscle and TRG 
dissection. Masseter tissue was evaluated histopathologi-
cally and TRG tissue was analyzed for P2X3 receptor mRNA 
expression by using quantitative real-time polymerase 
chain reaction (PCR) analysis. To assess the P2X3 receptor 
involvement in nocifensive behavior, two doses (6 and 60 
μg/50 μL) of selective P2X3 antagonist A-317491 were ad-
ministrated into the inflamed masseter muscle 4 days after 
the CFA injection. Bilateral HWT was measured at 15-, 30-, 
60-, and 120-minute time points after A-317491 adminis-
tration.
Results HWT was bilaterally reduced after the CFA injec-
tion (P <0.001). Intramasseteric inflammation was con-
firmed ipsilaterally to the CFA injection. Quantitative real-
time PCR analysis demonstrated enhanced P2X3 expression 
in TRG ipsilaterally to CFA administration (P < 0.01). In com-
parison with controls, the dose of 6 μg of A-317491 signifi-
cantly increased bilateral HWT at 15-, 30-, and 60-minute 
time points after the A-317491 administration (P < 0.001), 
whereas the dose of 60 μg of A-317491 was efficient at all 
time points ipsilaterally (P = 0.004) and at 15-, 30-, and 60-
minute time points contralaterally (P < 0.001).
Conclusion Unilateral masseter inflammation can induce 
bilateral allodynia in rats. The study provided evidence that 
P2X3 receptors can functionally influence masseter muscle 
allodynia and suggested that P2X3 receptors expressed in 
TRG neurons are involved in masseter inflammatory pain 
conditions.
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Temporomandibular disorders (TMDs) are a group of mus-
culoskeletal conditions affecting the masticatory system 
and resulting in disability and pain. Common TMD symp-
toms include reduced mouth opening and jaw mobility, 
jaw locking, and temporomandibular joint (TMJ) noises. 
The most prominent symptom is pain typically located in 
the masseter muscles (1).
The cause of TMDs remains unclear. Recent studies on 
TMDs focus on changes in pain mechanisms rather than 
etiological factors, because even patients with negligible 
anatomical changes may develop pain sensations, and 
unilateral masseter or TMJ inflammation can provoke bilat-
eral and/or referred hyperalgesia and/or allodynia (2-4).
New findings point out the key role of receptor-regulat-
ed ion channels in peripheral and central neurons in pain 
mechanisms. Trigeminal ganglion (TRG) neurons express 
different receptor types and their expression changes, and 
their ability to bind ligands characteristic of tissue damage 
imply their significance in pain transmission and, therefore, 
in the etiopathogenesis of TMDs (5-7).
The purinergic signaling system, especially P2 and P2X re-
ceptor families, is one of the most important receptor sys-
tems involved in pain mechanisms. There are at least 12 
P2X purinoceptors expressed in the central and peripheral 
neurons and involved in neurotransmission, neuromodula-
tion, and neuromuscular transmission. They are all ATP-gat-
ed cation channels, although there are also other agonists 
with restricted subtype selectivity (8,9).
Although all P2X receptors are present in sensory neurons, 
P2X3 receptors are expressed at the highest levels, espe-
cially in nociceptive C and Aδ fibers (10,11). Recent stud-
ies have shown that P2X3 plays an important role in differ-
ent pain states including migraine pain states (12), diabetic 
neuropathic pain (13), bone cancer pain conditions (14), 
and many others. P2X3 as recently been identified as one of 
the most important in still unclear signaling mechanisms 
underlying orofacial pain (15,16). The stretching and ec-
centric contraction of the masseter muscle induces hype-
ralgesia and up-regulation of P2X3 expression leading to 
enhanced nociceptor responsiveness to increased ade-
nosine triphosphate (ATP) levels within occurring myofiber 
damage (17). A recent study determined P2X1, P2X3, and 
P2X2/3 receptors involvement in carrageenan-induced TMJ 
inflammatory hyperalgesia (18). Conversely, there are data 
suggesting that P2X purinoceptors, especially P2X3 and 
P2X2/3, could be involved in antinociception (19,20).
Although the underlying mechanism for masseter muscle 
pain is still unclear, recent studies highlight the involve-
ment of various receptors in the etiopathogenesis of TMDs 
and propose various antagonist and/or agonists as possi-
ble therapeutic agents. Previous studies have investigated 
receptor-regulated ion channel expression in various pain 
models, but not in the masseter inflammation model. As 
masseter pain is the most prominent symptom in patients 
with TMDs, and P2X3 receptors seem to be involved in no-
ciception originating from orofacial region, we decided to 
investigate the expression of P2X3 receptors in TRG after 
eliciting bilateral allodynia induced by unilateral masseter 
inflammation and effects of direct unilateral intramuscular 
administration of two doses of specific P2X3 antagonist on 
bilateral pain response. Out hypothesis was that bilateral 
masseter allodynia after unilateral masseter inflammation 
results from P2X3 receptor up-regulation at TRG level and 
that unilateral intramasseteric administration of P2X3 an-
tagonist leads to bilateral masseter allodynia attenuation.
MATERIAL AND METHODS
Experimental animals
Experiments were performed on 10- to 12-week-old male 
Wistar rats weighing 250-300 g (n = 52). Before any animal 
manipulation, the animals were housed under controlled 
environment for 7 days to avoid possible stress influence 
due to transport from the breeding facility. The rats were 
housed in groups of two to three per cage under a con-
trolled ambient at a temperature of 20°C to 24°C, humid-
ity of 45% to 65%, in a 12h/12h light/dark cycle, and with 
access to food and water ad libitum. All efforts were made 
to minimize animal suffering and reduce the number of 
animals. All experimental protocols involving animals were 
performed in accordance with the Croatian regulations 
(Official Gazette 135/06, 37/13, and 47/09) and approved 
by the Croatian Ministry of Agriculture, Cabinet for Veteri-
nary and Food Safety, and the School’s Ethics Committee.
The experiments were performed in two phases. In the 
first phase, bilateral pain model was established by induc-
ing unilateral masseter inflammation in 16 animals. Eight 
of these 16 animals received complete Freund’s adjuvant 
(CFA) and served as the experimental group. The other 8 
animals received saline solution and served as the con-
trol group. Twelve of these 16 animals (6 from the experi-
mental and 6 from the control group) were subsequently 
subjected to tissue isolation. The masseter muscle was 
isolated for histopathological examination and TRG 
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was isolated for quantitative real-time polymerase chain 
reaction (PCR) analysis. In the second phase, the effect of 
P2X3 receptor antagonist administration on the nocifen-
sive behavior was examined in 36 animals (Table 1).
Bilateral pain induced by unilateral masseter muscle 
inflammation
In the first phase, all animals (n = 16) were submitted to 
masseter inflammation induction as described in previous 
studies (3,21,22). Briefly, animals were anesthetized with 
4% isoflurane (Forane, Abbott Laboratories Ltd, Queen-
borough, UK) in O2:N2 = 1:2 mixture to abolish righting and 
corneal reflexes. Eight animals were injected with 50 μL 
CFA (Sigma F5881, Sigma-Aldrich, Saint Louis, MO, USA, 0.5 
mg/mL, heat killed Mycobacterium tuberculosis suspend-
ed in oil:saline at 1:1 emulsion) in the mid-region of right 
masseter muscle. The exact injection site was established 
by palpating the masseter muscle between the angle of 
the mandible and the zygomatic bone. Upon contacting 
the mandible, the needle was slowly withdrawn into the 
mid-region of the masseter muscle. CFA and saline admin-
istrations were made via a 27-gauge needle and complet-
ed within 5-10 seconds. Animals in the control group (n = 8) 
received 0.9% saline injection in the same manner. All so-
lutions were freshly prepared before use. Animals were 
closely monitored on daily basis for evidence of edema af-
ter injection of CFA or saline. Development of masseter in-
flammation was examined by a histopathological method. 
Behavior assessment was performed as the next step to 
confirm bilateral allodynia development.
Behavior assessment. We defined mechanical allodynia as 
the presence of a nocifensive behavioral response evoked at 
a mechanical threshold that previously did not evoke a nocif-
ensive response. Changes in nocifensive behavioral respons-
es were evaluated by using previously described methods 
(3,23,24). To confirm bilateral allodynia, the nocifensive be-
havior response after unilateral CFA or saline injection into 
the masseter muscle was measured bilaterally at differ-
ent time points using a von Frey anesthesiometer 
(VFA; type 2391, IITC Inc., Woodland Hills, CA, USA) with the 
tip size of 1.0 mm. The threshold was defined as the lowest 
force necessary to evoke an active withdrawal of the head 
from the probing tip. The probing tip attached to the VFA 
was applied to the mid-region of the masseter muscle five 
times at one minute intervals; the average value of these five 
measurements was considered the withdrawal threshold.
Before the VFA measurements, animals were accustomed 
to stand unrestrained on the experimenter’s glove. Me-
chanical thresholds were then tested by probing the 
masseter muscles bilaterally before and on Day 4 after CFA 
or saline injection, when the nocifensive response is most 
prominent (3). A baseline mechanical threshold for evok-
ing the head withdrawal responses was determined 15 
minutes before the CFA or saline injection. All behavioral 
tests were conducted under blind conditions, ie, by an in-
vestigator blind to grouping and drug administration.
Administration of P2X3 receptor antagonist
We initially examined the effect of intramasseteric injection 
of either P2X3 receptor antagonist or saline on the baseline 
head withdrawal threshold (HWT) in 36 animals (Table 1) 
(3,25). Animals were lightly anesthetized with 2% isoflu-
rane in O2:N2 = 1:2 mixture before the administration of 
P2X3 receptor antagonist A-317491 (A2979, Sigma-Aldrich, 
Saint Louis, USA), which is a selective P2X3 antagonist with 
very limited penetration to the central nervous system 
(CNS) (26). The P2X3 receptor antagonist A-317491 was ad-
ministered at the dose of either 6 µg/50 µL (D6; n = 6) or 
60 µg/50 µL (D60, n = 6). The animals in the control group 
(n = 6) were administered 50 µL of saline solution. The HWT 
was measured before and 15, 30, 60, and 120 minutes after 
the A-317491 or saline administration.
To evaluate the effect of P2X3 receptor antagonist on bilat-
eral mechanical threshold after unilateral masseter inflam-
mation (Table 1), the animals were unilaterally injected 
with CFA under 4% isoflurane anesthesia. On Day 4 after 
the intramasseteric CFA injection, the bilateral nocifensive 
response was measured to verify the development of bilat-
eral mechanical allodynia. After the behavioral evaluation, 
each animal was lightly anesthetized with 2% isoflurane. 
The P2X3 receptor antagonist A-317491 was diluted in dis-
tilled water and administered in two different doses, ie, 6 
µg/50 µL (D6; n = 6) or 60 µg/50 µL (D60; n = 6). The sham 
rats in the control group (n = 6) were injected with 0.9% sa-
line in the corresponding volume. All solutions were fresh-
ly prepared before use, and the dose and volume of P2X3 
TABLE 1. Number of animals included in the testing of the ef-
fect of P2X3 receptor antagonist administration*
P2X3 receptor antagonist administration
sham rats CFA-injected rats
saline D6 D60 saline D6 D60
No. of rats 6 6 6 6 6 6
* Abbreviations: CFA - complete Freund’s adjuvant; D6 - dose of 6 
µg/50 µL of P2X3 receptor antagonist A-317491; D60 - dose of 60 µg/50 
µL of P2X3 receptor antagonist A-317491.
533Tariba Knežević et al: P2X
3
 in masseter muscle allodynia in rat
www.cmj.hr
antagonist were based on previous studies (15,27). The 
A-317491 was administered unilaterally to the mid-region 
of the masseter muscle. The exact injection site was estab-
lished by palpating the masseter muscle between the an-
gle of the mandible and the zygomatic bone. Upon con-
tacting the mandible, the needle was slowly withdrawn 
into the mid-region of the masseter muscle. CFA, A-317491, 
and saline were administered via a 27-gauge needle within 
5-10 seconds. The HWT was re-evaluated at 15, 30, 60, and 
120 minutes after the A-317491 injection (3,23).
Tissue isolation, preparation, and analysis
On Day 4 after the unilateral intramasseteric administration 
of CFA or saline (Table 1), the final behavioral evaluation 
was performed. The rats were decapitated and tissue iso-
lation was performed in 6 rats from each group. Bilateral 
masseter muscles were harvested for histopathological 
inflammation assessment. Bilateral TRGs were isolated for 
the evaluation of the P2X3 receptor mRNA expression. All 
tissues were frozen in liquid nitrogen and stored at -80°C 
until processed.
Histopathological evaluation of masseter muscle tissue. 
Both ipsilateral and contralateral masseter muscles were 
fixed in 4% paraformaldehide, embedded in paraffin, cut 
at 40 µm, and stained with hematoxylin and eosin.
Quantitative real-time PCR. After rat decapitation and bi-
lateral harvesting of TRG, tissue samples sized to 1 cm2 
were frozen in 500 µL of RNAlater (Ambion, Austin, TX, 
USA) at -80°C. The RNA isolation process involved tissue 
homogenization performed using a MagNA Lyser instru-
ment (Roche Life Sciences, Mannheim, Germany). The 
RNA isolation protocol was continued using NucleoSpin 
RNA kit (Macherey-Nagel, Düren, Germany) according to 
the manufacturer’s instructions. The concentration of to-
tal RNA was determined using Qubit 3.0 instrument and 
Qubit RNA Broad Range reagent (Life technologies, Carls-
bad, CA, USA). Transcription was performed using High Ca-
pacity cDNA kit (Applied Biosystems, Foster City, CA, USA). 
In the process, 500 ng of total RNA was used. Random hex-
amer primers provided with the kit were used for reverse 
transcription. cDNA libraries were stored at -25°C prior to 
the quantification process.
The expression levels of P2X3-specific mRNA were mea-
sured using Applied Biosystems 7500 Fast Real-Time PCR 
and Taqman Gene Expression Assays (Applied Biosys-
tems) for P2X3 (Rn00579301_m1) as the target and beta-
actin (Rn00667869_m1) and GAPDH (Rn01775763_g1) as 
housekeeping genes (27,28). The evaluation of two differ-
ent housekeeping genes was used to normalize the values 
of the cDNA libraries used in the real-time quantification 
and minimize the RNA isolation and transcription errors. 
The P2X3 relative expression levels were determined by the 
2-ΔΔCt method with to compare the expression of genes of 
interest with that of housekeeping genes.
Statistical analysis
Data are presented as mean ± standard deviation (SD). All 
measurements were tested with Kolmogorov-Smirnov test 
for the normality of distribution. To establish the changes in 
mechanical HWT before and after the CFA or saline injection, 
a linear mixed model was used. The one-sample t test was 
used to analyze differences in P2X3 mRNA expression levels 
between the two groups. For statistical analysis of behavior-
al measurements between the groups of rats injected with 
CFA and P2X3 antagonist or saline afterwards, a mixed ANO-
VA was used with time points as within-subjects factor and 
group as between-subject factor. P < 0.05 was considered 
statistically significant. All statistical tests were performed 
using SPSS 21.0 software (SPSS Inc., Chicago, SAD).
RESULTS
Unilateral intramasseteric CFA injection induced 
ipsilateral masseter muscle inflammation
The unilateral intramasseteric CFA injection resulted in 
edema and redness in the injection area. No such changes 
were observed in the masseter muscle contralateral to the 
injection site in the CFA-injected rats, nor in the ipsilateral 
and contralateral masseter muscles in saline-injected rats.
The intramasseteric CFA injection induced unequivocal 
histological signs of inflammation including numerous 
vacuoles and massive infiltration of granular leukocytes at 
the CFA injection site (Figure 1A). No histological signs of 
inflammation were perceived in the contralateral masseter 
muscle of CFA-injected rats nor in the masseter muscles of 
saline-injected rats (Figure 1B and 1C).
Bilateral mechanical allodynia induced by unilateral 
intramasseteric CFA injection
The CFA-injected rats (n = 8) showed the reduction in 
both ipsilateral and contralateral HWT in comparison 
with saline-injected control rats (n = 8). A statisti-
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cally significant decrease was identified in bilateral HWT 
4 days after the CFA injection (P < 0.001; Figure 2). Saline 
injection in the masseter muscle did not affect HWT on 
either side (Figure 2).
FIgURE 1. Histopathological examination of the masseter 
muscle tissue 4 days after unilateral complete Freund’s adju-
vant (CFA) injection showed unequivocal inflammation signs 
(hematoxylin and eosin staining, ×20). The masseter tissue 
ipsilaterally to CFA injection showed clear signs of inflam-
mation – inflammatory cells infiltration and vacuoles (A). 
Contralaterally to CFA administration, no signs of inflamma-
tion are visible in the masseter muscle tissue (B). The masseter 
tissue after saline injection showed no signs of inflammation 
on either side (C).
FIgURE 2. Head withdrawal threshold was statistically lower 
bilaterally 4 days after complete Freund’s adjuvant (CFA) 
injection into the masseter muscle region. No differences were 
observed between the CFA-injected group and saline-injected 
control group before CFA or saline injection either ipsilater-
ally or contralaterally. Four days after the CFA injection, a 
statistically significant differences were observed ipsilaterally 
and contralaterally (P < 0.001 for both) in comparison with 
the saline-injected control group. The results are presented as 
mean values, using a linear mixed model. Each group included 
8 animals.
FIgURE 3. P2X3 receptor mRNA expression was up-regulated in 
ipsilateral trigeminal ganglia (TRg). A statistically significant in-
crease in P2X3 receptor mRNA expression was observed at TRg 
ipsilaterally to the masseter muscle injected with complete 
Freund’s adjuvant (CFA) in comparison to P2X3 expression in 
ipsilateral TRg in control animals (P = 0.010). Although the 
P2X3 receptor mRNA expression was elevated, no statistically 
significant differences were observed between experimental 
and control groups at TRg contralaterally to the CFA-injected 
masseter muscle (P = 0.105). Results are presented as me-
dian ± standard deviation. Each group included 6 animals. As-
terisk indicates a statistical significance of P < 0.05 (one-sample 
t test) between the CFA- and saline-injected groups.
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Masseter muscle inflammatory allodynia enhanced 
P2X3 expression in the trigeminal ganglion
Changes in the expression levels of P2X3 receptor mRNA 
in both ipsilateral and contralateral TRGs after the uni-
lateral CFA injection into the masseter muscle were de-
termined by the quantitative real-time PCR technique. 
Bilateral TRGs were harvested 4 days after the CFA injec-
tion. A statistically significant increase in the P2X3 mRNA 
levels was found in the TRG ipsilaterally to CFA injection 
(P = 0.010; Figure 3) in comparison with the controls. Con-
tralateral P2X3 mRNA levels were elevated, but they did 
not show significant differences in comparison with the 
controls (P = 0.105; Figure 3).
Unilateral administration of P2X3 receptor antagonist 
attenuated bilateral masseter muscle allodynia
The specific P2X3 receptor antagonist A-317491 was unilat-
erally administered into the masseter muscle of rats to test 
the possible effect of P2X3 receptor changes on bilateral al-
lodynia induced by unilateral masseter inflammation.
To exclude the possible influence of the P2X3 receptor an-
tagonist A-317491 on baseline HWT in untreated rats, HWT 
was measured bilaterally before and after the intramasse-
teric injection of the P2X3 receptor antagonist A-317491 in 
the D6 (n = 6) and D60 (n = 6) groups of rats and before and 
after the intramasseteric injection of saline in control rats. 
FIgURE 4. Unilateral administration of A-317491 in two different doses (6 µg [D6] and 60 µg [D60]) attenuated bilateral masseter 
inflammatory allodynia at 15-, 30-, and 60-minute time points. No significant changes were observed between the groups in head 
withdrawal threshold (HWT) measurements either ipsilaterally or contralaterally to A-317491 or saline injection in sham rats (A, B). 
Ipsilaterally to complete Freund’s adjuvant (CFA) injection, significant HWT increase in comparison with controls was observed in 
D6 groups at 15-, 30-, and 60-minute time points after intramasseteric A-317491 injections (P < 0.001). At 120-minute time point, 
the difference between the D6 and saline-injected groups was not significant (P = 0.491). In the D60 group, significant differences 
were found at all observed time points in comparison with controls (P ≤ 0.004). Differences between D6 and D60 groups appeared 
at 120-minute time point (P = 0.042) (C). In the contralateral masseter muscle, the HWT increase occurred at 15-, 30-, and 60-minute 
time points in both A-317491 groups compared with controls. No significant difference was observed at 120-minute time point. No 
significant difference was found between D6 and D60 groups (D). Data are presented as mean values (mixed ANOVA). Each group 
included 6 animals. Asterisks indicate statistical significance of *P < .05; **P < 0.01; ***P < 0.001 for difference between D6 and saline-
injected groups after A-317491 administration. Caret indicates a statistical significance of ^P < 0.05; ^^P < 0.01; ^^^P < 0.001 for 
difference between D60 and saline-injected groups after A-317491 administration.
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No statistically significant differences were found between 
the A-317491-injected and saline-injected groups of rats 
at any observed time point either ipsilaterally or contralat-
erally to A-317491 or saline injection (Figures 4A and 4B). 
Neither dose of A-317491 or saline influenced the bilateral 
baseline values of HWT at any observed time points.
On Day 4 after the CFA injection, HWT values significantly 
decreased in all groups (P ≤ 0.001 for all), reconfirming the 
allodynia occurrence both ipsilaterally and contralaterally 
to the CFA injection (Figures 4C and 4D). Ipsilaterally to CFA 
and A-317491 or saline injections, a significant increase in 
HWT occurred 15, 30, and 60 minutes after the A-317491 
injection in the D6 group in comparison with the saline-in-
jected control group (P < 0.001), whereas in the D60 group, 
a significant increase in HWT occurred at 15, 30, 60, and 
120 minutes after the A-317491 injection in comparison 
with saline-injected control group (P < 0.001 at 15-, 30-, 
and 60-minute time points; P = 0.004 at 120-minute time 
point). No significant differences were noticed between 
D6 and D60 groups at any time points except at 120-min-
ute time point (P = 0.042; Figure 4C).
Contralaterally to CFA and A-317491 or saline administra-
tion, allodynia attenuation occurred at 15-, 30-, and 60-
minute time points in both D6 and D60 groups in com-
parison with the saline-injected control group (P < 0.001). 
No significant differences were noticed at 120-minute time 
point (P = 0.990 for D6 group, P = 0.077 for D60 group). Be-
tween D6 and D60 groups, no statistically significant differ-
ences were found at any time point (Figure 4D).
DISCUSSION
We aimed to determine the role of P2X3 receptors in 
pathophysiological mechanisms underlying bilateral al-
lodynia induced by unilateral masseter inflammation and 
found that unilateral masseter inflammation enhances 
P2X3 receptor expression within neurons of the ipsilateral 
TRG. No changes in the P2X3 receptor expression were ob-
served in the contralateral TRG neurons.
P2X3 receptors are involved in many pain states within the 
orofacial area. Hyperalgesia induced by occlusal interfer-
ence resulted in enhanced P2X3 mRNA expression and in-
creased frequency of P2X3-immunoreactive small-sized TRG 
neurons and was attenuated by P2X3 antagonist adminis-
tration (29). Pain transmission in tooth is regulated through 
ATP transport in odontoblasts and signal transduction to 
P2X3 receptors on pulp axons (30). Noma et al (15) re-
ported increased P2X3 expression in masseter hyperalgesia 
following excessive masseter contraction. As mentioned 
earlier, eccentric muscle contraction and muscle stretching 
can lead to hyperalgesia and P2X3 up-regulation in afferent 
TRG neurons (17). Unilateral TMJ arthritis enhanced P2X3 re-
ceptors expression in the ipsilateral small TRG neurons 15 
days after CFA injection. Unilateral P2X agonist administra-
tion resulted in bilateral TMJ pain (17). It has been suggested 
that lip inflammation leads to increased P2X3 receptors ex-
pression in TRG mediated by calcitonin gene-related pep-
tide and could be involved in ectopic mechanical allodynia 
(31). In addition, some previous studies have determined 
enhanced P2X3 receptors expression in dorsal root ganglion 
(DRG) after muscle inflammation (32). However, some stud-
ies claim that P2X3-expressing TRG neurons considerably 
differ from DRG afferent neurons, suggesting differences in 
pain transmission depending on the location of pain occur-
rence, and that the underlying mechanisms of pain originat-
ing from different body regions are unique (21,22).
We investigated whether unilateral masseter inflamma-
tion led to changes in P2X3 receptor expression at bilateral 
TRG level. Our quantitative real-time PCR analysis results 
showed increased P2X3 receptor expression in TRG both 
ipsilateral and contralateral to CFA injection, but only the 
changes in the ipsilateral inflamed TRG showed statistical 
significance in comparison with controls, leading us to a 
conclusion that the up-regulation of P2X3 receptors is re-
lated to inflammation and that allodynia in the contralater-
al non-inflamed masseter muscle probably arises from the 
changes in expression of some other receptor-regulated 
ion channels involved in neuromuscular pain transmission. 
It seems that the inflammation is responsible for changes 
in P2X3 expression at primary neuronal level.
In addition, we demonstrated that ipsilateral adminis-
tration of P2X3 receptor antagonist, A-317491, into the 
masseter muscle results in bilateral masseter pain allevia-
tion in previously unilaterally CFA-injected rats.
To demonstrate P2X3 receptor involvement, we tested the 
effect of unilateral administration of P2X3 receptor antag-
onist on bilateral nocifensive response in previously CFA-
injected rats. Our results showed that unilateral CFA injec-
tion in the central region of masseter muscle followed by 
ipsilateral injection of A-317491 significantly increased the 
HWT values both ipsilateral and contralateral to CFA injec-
tion site. A-317491 decreased nocifensive response on the 
side ipsilateral to inflammation and A-317491 injection due 
to its direct influence on P2X3 receptors; however, changes 
537Tariba Knežević et al: P2X
3
 in masseter muscle allodynia in rat
www.cmj.hr
also occurred on the contralateral side. Because A-317491 
is an antagonist with limited CNS penetration, these data 
also suggest that unilateral inflammation results in bilater-
al allodynia due to P2X3 receptor enhancement ipsilateral 
to inflammation, while contralateral allodynia is more like-
ly related to other receptor-regulated ion channel expres-
sion changes induced by the CNS pathways that seem to 
be crucial in bilateral pain development after unilateral in-
flammation. Recent studies have demonstrated the impor-
tant role of trigeminal interpolaris/caudalis (Vi/Vc) transition 
zone and rostral ventromedial medulla (RVM) in processing 
trigeminal pain arising from masseter muscle inflammation 
and in the development of bilateral hyperalgesia/allodynia. 
It has been suggested that contralateral hyperalgesia in the 
orofacial region is mediated through descending facilitato-
ry mechanisms of the RVM-Vi/Vc circuitry (33-35). It has also 
been suggested that inhibition of glia and inflammatory cy-
tokines cascade blockage following inflammation provides 
pain relief (35). Taking into consideration that A-317491 has 
a poor ability to penetrate the blood-brain barrier, its bilat-
eral pain alleviation effect may arise from its blockage of 
P2X3 receptors at TRG neurons and interrupted cytokines 
cascade leading to activation of CNS pathways.
The significant difference between D6 and D60 groups at 
120-minute time point ipsilateral to A-317491 administra-
tion lead us to the conclusion that the lower A-317491 dose 
could be enough to obtain analgesic effect, but further ex-
periments are needed to establish the appropriate dose.
An additional finding of our study was that unilateral 
masseter inflammation led to bilateral masseter pain. Al-
though pain sensation development and mechanisms in-
volved in various pain models have been extensively in-
vestigated (15,29,36-38), only limited number of studies 
focused on bilateral pain (3,16,36,39). A few research proj-
ects reported confusing data on whether unilateral inflam-
mation can provoke bilateral nocifensive behavior (36,40), 
whereas several studies reported that unilateral inflamma-
tion resulted in bilateral allodynia (3,41,42).
We managed to establish a bilateral masseter pain mod-
el after unilateral inflammation. We used the CFA-induced 
model of inflammatory pain commonly used in studies in-
vestigating orofacial pain (3,43-45). Our findings confirm 
that unilateral masseter inflammation can cause bilater-
al nocifensive behavior on Day 4 after CFA injection. We 
chose the Day 4 time point according to previous studies 
reporting that most prominent bilateral allodynia occurs 4 
days after the CFA injection (3). Pain develops in both in-
flamed and contralateral non-inflamed masseter area, sug-
gesting the activation of signaling pathways at both local 
peripheral level and CNS level.
There were several limitations of our study. The number of 
experimental animals was low and we did not investigate 
the changes at the CNS level. Also, we used the 60 µg/50 
µL dose of P2X3 receptor antagonist A-317491, which had 
already been proved effective in other pain models, ie, we 
could have used a different, lower dose of A-317491.
In conclusion, our findings demonstrate that unilateral 
masseter inflammation can induce bilateral allodynia in 
rats and enhanced P2X3 receptors expression in the TRG 
ipsilateral to inflammation induction, ie, that bilateral 
masseter allodynia induced by unilateral masseter inflam-
mation is related to the enhanced P2X3 receptor expres-
sion at TRG ipsilaterally to inflammation. Our study results 
showed that unilateral P2X3 antagonist administration into 
the masseter muscle led to bilateral alleviation of masseter 
allodynia, suggesting that P2X3 receptors expressed in TRG 
neurons can functionally influence masseter allodynia and 
are involved in pain conditions related to masseter inflam-
mation. Contralateral masseter allodynia is likely to be me-
diated by other receptor-regulated ion channels.
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